MassARRAY-based KRAS and GNAS hotspot mutation analysis of cystic fluid enables accurate classification of pancreatic cystic lesions

doi:10.3748/wjg.v32.i13.115710

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 13

This Article

(34)

(33)

(1)

(0)

(1)

(594)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Apr 7, 2026; 32(13): 115710
Published online Apr 7, 2026. doi: 10.3748/wjg.v32.i13.115710

Table 3 Performance of different diagnostic modalities

	Sensitivity (95%CI)	Specificity (95%CI)
Identification of mucinous neoplasms among all PCLs
Integrated prediction model	62.7% (50.4%-75.1%)	95.2% (88.8%-100%)
KRAS/GNAS mutation panel	40.7% (28.1%-53.2%)	100% (100%-100%)
Clinical characteristics and serum markers	37.3% (24.9%-49.6%)	95.2% (88.8%-100%)
Identification of IPMNs among all PCLs
Integrated prediction model	82.6% (67.1%-98.1%)	100% (100%-100%)
KRAS/GNAS mutation panel	52.2% (31.8%-72.6%)	100% (100%-100%)
Clinical characteristics and serum markers	78.3% (61.4%-95.1%)	80.8% (72.0%-89.5%)
Identification of mucinous neoplasms among PCLs in pancreatic head
Integrated prediction model	87.5% (71.3%-100%)	100% (100%-100%)
KRAS/GNAS mutation panel	56.2% (31.9%-80.6%)	100% (100%-100%)
Clinical characteristics and serum markers	62.5% (38.8%-86.2%)	100% (100%-100%)
Identification of IPMNs among PCLs
Integrated prediction model	84.6% (65%-100%)	100% (100%-100%)
KRAS/GNAS mutation panel	46.2% (19.1%-73.3%)	100% (100%-100%)
Clinical characteristics and serum markers	69.2% (44.1%-94.3%)	92.9% (79.4%-100%)

IPMNs: Intraductal papillary mucinous neoplasms; PCLs: Pancreatic cystic lesions.

Full Size Table

Citation: Diao WF, Cui M, Chen TQ, Xiao JH, Yang S, Zheng QY, Xu RY, Han XL, Hu Y. MassARRAY-based KRAS and GNAS hotspot mutation analysis of cystic fluid enables accurate classification of pancreatic cystic lesions. World J Gastroenterol 2026; 32(13): 115710
URL: https://www.wjgnet.com/1007-9327/full/v32/i13/115710.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i13.115710

Diao WF, Cui M, Chen TQ, Xiao JH, Yang S, Zheng QY, Xu RY, Han XL, Hu Y. MassARRAY-based KRAS and GNAS hotspot mutation analysis of cystic fluid enables accurate classification of pancreatic cystic lesions. World J Gastroenterol 2026; 32(13): 115710 [DOI: 10.3748/wjg.v32.i13.115710]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.